Bailey Renger

For Black Friday, we did a thing... Blood Friday. How you can get 100% off:

superpower hq triple bunk is officially official

I’m going to build an organoid avatar of myself. Thousands of miniature Bryan Johnsons grown on cell culture dishes, each replicating my cellular and organ biology. This living model will let me test the efficacy of supplements, drugs, and nutrition to accelerate safe and measure progress against aging. Details: The potential of stem cell derived organoids is to enable toxicity screenings for drug discovery and complex treatment regiments. This same benefit can be realized for longevity supplementation, nutrition, and Rx protocols. Becoming the most measured person in history allowed my organs to speak, but the drawback is that there’s only one copy of me for testing. This means I can only tweak one or a handful of variables at a time to explore their effects. A single copy of me limits the number of things I can test simultaneously, slowing the speed of progress. These limitations can be resolved by scaling me up using personalized, stem cell-derived organoids. We are currently giving this serious consideration. Here's a rough workflow: A blood sample is taken, some cells are isolated (PBMCs) and reprogrammed into induced pluripotent stem cells (iPSCs). These cells are then propagated in cultures. Using special lab treatments and conditions, they are coaxed to differentiate and grow into mini-organs, or organoids. These organoids carry my exact DNA. Although the reprogramming process erases most epigenetics acquired in my life, bringing the cells back to a newborn-like state, we can think of these organoids as "Baby Bryans" available to test interventions. Organoid function and phenotype can be monitored using computational models, which can extrapolate the organoid's behavior to predict effects on the actual organs in my body. These organoids can be hooked together into one artificial circulation, creating hundreds or thousands of "mini Bryans." These will allow us to test each ingredient and intervention separately, as well as particular combinations. The level of evidence and sophistication of organ-on-chip model has seen rapid progress in the last decade Initial prototypes utilized interconnected 2-D and spheroid "organ-on-chip" cultures to successfully model the metabolism, toxicity, and biodistribution of drugs and their metabolites, including liver-kidney, liver-lung, and liver-brain interactions. The use of induced pluripotent stem cells (iPSCs) coupled with 3D-printed scaffolds to generate spheroids and organoids paved the way for these systems in personalized medicine. This approach enables accurate, personalized, case-by-case predictions for drug interaction, efficacy, and toxicity. These systems can even model systemic disease states, such as blood-brain barrier permeability, neurotoxicity, lung and pancreas cystic fibrosis, cancer metastasis, and responsiveness to chemotherapy. The next iteration of organoids rely on computational models, promising to evolve these systems from modeling extreme toxicity and disease states to the more delicate field of predicting chronic toxicity and harms from drugs in development. This granularity will enable optimization of personal drug and supplement regimens with cellular and molecular level accuracy, a feat normally challenging to track within the complexity of the living body. The field is maturing from merely generating organoids to building in-silico avatars of one's body based on insights collected from cultured organoids. On the pharmaceutical side, these systems can already accelerate discovery by predicting drug candidate toxicity before they transition into expensive clinical trials. On the longevity and personal health side, this means we will soon no longer have to speculatively test interventions and therapies on ourselves based solely on general population data. My organoid avatars will undertake the heavy lifting of detecting and predicting toxicity, harm, and likelihood of efficacy.